Stay updated on Sub-Lingual Dexmedetomidine in Agitation Clinical Trial
Sign up to get notified when there's something new on the Sub-Lingual Dexmedetomidine in Agitation Clinical Trial page.

Latest updates to the Sub-Lingual Dexmedetomidine in Agitation Clinical Trial page
- Check5 days agoChange DetectedThe clinical trial record for sublingual dexmedetomidine for agitation associated with dementia is displayed, with details on its completed Phase 1b/2 study, treatment arms, measures, and participant criteria.SummaryDifference60%

- Check12 days agoChange DetectedThe footer revision label updates from v3.7.2 to v3.8.0, while the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check19 days agoChange DetectedA site-wide NIH banner was added, announcing a transition from the term “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.SummaryDifference1%

- Check26 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 on the study page’s 403 error screen.SummaryDifference0.2%

- Check33 days agoChange DetectedThe footer revision label was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check47 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, effectively blocking access to the study details. This change represents a loss of core page functionality for this study page.SummaryDifference0.5%

Stay in the know with updates to Sub-Lingual Dexmedetomidine in Agitation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sub-Lingual Dexmedetomidine in Agitation Clinical Trial page.